Breaking News Instant updates and real-time market news.

ABT

Abbott

$38.73

0.63 (1.65%)

, STJ

Acquired by ABT

$79.67

0.77 (0.98%)

12:41
11/23/16
11/23
12:41
11/23/16
12:41

EU clears Abbott-St. Jude Medical merger, Dow Jones says

The EU has cleared the proposed merger of Abbott (ABT) and St. Jude Medical (STJ) after Abbott agreed to fully divest its Vado business as well as St. Jude's global vessel closure devices business, Dow Jones reports.

ABT

Abbott

$38.73

0.63 (1.65%)

STJ

Acquired by ABT

$79.67

0.77 (0.98%)

ABT Abbott
$38.73

0.63 (1.65%)

10/25/16
RBCM
10/25/16
NO CHANGE
RBCM
Abbott should be bought on recent weakness, says RBC Capital
After Abbott reported slightly stronger than expected Q3 results, RBC Capital analyst Glenn Novarro predicts that the company's 2016 EPS will come in at $2.63, excluding its acquisition of Alere. The analyst thinks that Abbott's EPs can rise to $2.93 in 2018, excluding the Alere deal, driven by lower interest costs and higher synergies. He says that recent weakness in the stock has been caused by issues that are "either transient or can be offset." The analyst keeps a $48 price target and Outperform rating on the stock.
10/20/16
LEER
10/20/16
NO CHANGE
Target $45
LEER
Market Perform
Abbott selloff overdone as long-term fundamentals remain intact, says Leerink
Leerink analyst Danielle Antalffy believes the selloff in Abbott's shares is overdone, as long-term fundamentals remain intact. With another "solid" quarter in hand, despite a weaker than expected Nutritionals performance, the analyst believes the company seems to remain "solidly" on track to deliver improving operational results in 2017, after a year in which it is reshaping the portfolio by acquiring higher-growth assets and shedding slower, lower-margin businesses. Antalffy reiterates a Market Perform rating on the stock but lowered her price target on the shares to $45 from $48.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
STJ Acquired by ABT
$79.67

0.77 (0.98%)

09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.57

0.03 (0.05%)

19:34
02/22/17
02/22
19:34
02/22/17
19:34
Hot Stocks
Market researcher: Starbucks consumer perception dips after refugee hiring news »

Market researcher YouGov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

LB

Labarge

$58.13

0.43 (0.75%)

19:33
02/22/17
02/22
19:33
02/22/17
19:33
Hot Stocks
L Brands sees Q1 comps down high-single to low-double digits »

Sees Q1 Go-Forwards comps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

19:32
02/22/17
02/22
19:32
02/22/17
19:32
Hot Stocks
L Brands sees FY17 comps down low-single digits »

Sees FY17 Go-Forward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

F

Ford

$12.67

-0.02 (-0.16%)

19:30
02/22/17
02/22
19:30
02/22/17
19:30
Conference/Events
Ford to host sales conference call »

Ford U.S. Sales Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

GTLS

Chart Industries

$38.51

-1.21 (-3.05%)

19:27
02/22/17
02/22
19:27
02/22/17
19:27
Hot Stocks
Chart Industries CEO Samuel Thomas named executive chairman »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$273.51

-3.88 (-1.40%)

19:24
02/22/17
02/22
19:24
02/22/17
19:24
Periodicals
SolarCity leased with risky homeowners, has ties to foreclosure cases, NYT says »

In "dozens of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PRU

Prudential

$110.50

-0.72 (-0.65%)

, WFC

Wells Fargo

$58.36

0.11 (0.19%)

19:16
02/22/17
02/22
19:16
02/22/17
19:16
Hot Stocks
Prudential says could seek compensation from Wells Fargo over MyTerm products »

Prudential (PRU) stated…

PRU

Prudential

$110.50

-0.72 (-0.65%)

WFC

Wells Fargo

$58.36

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 13

    Apr

  • 06

    Jun

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PSA

Public Storage

$226.24

-1.49 (-0.65%)

19:15
02/22/17
02/22
19:15
02/22/17
19:15
Earnings
Public Storage reports Q4 core FFO $2.65, consensus $1.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

19:10
02/22/17
02/22
19:10
02/22/17
19:10
Periodicals
Credit Suisse probed for potentially aiding tax evasion, WSJ says »

Less than three years…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

LZB

La-Z-Boy

$28.40

-1.05 (-3.57%)

19:09
02/22/17
02/22
19:09
02/22/17
19:09
Downgrade
La-Z-Boy rating change  »

La-Z-Boy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

19:06
02/22/17
02/22
19:06
02/22/17
19:06
Syndicate
Cloud Peak 13.5M share Spot Secondary priced at $5.10 »

Credit Suisse, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SNAP

Snap Inc

18:47
02/22/17
02/22
18:47
02/22/17
18:47
Periodicals
Snap Inc nears $200M ad deal, NY Post says »

Snap Inc is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SBLK

Star Bulk Carriers

$9.59

0.29 (3.12%)

18:40
02/22/17
02/22
18:40
02/22/17
18:40
Earnings
Star Bulk Carriers reports Q4 EPS (29c), consensus (28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 22

    Mar

C

Citi

$60.62

0.07 (0.12%)

18:35
02/22/17
02/22
18:35
02/22/17
18:35
Periodicals
Citi forms regulatory affairs team in D.C., Bloomberg says »

Citi is forming a global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:34
02/22/17
02/22
18:34
02/22/17
18:34
Earnings
PRA Health sees FY17 EPS $3.08-$3.18, consensus $2.96 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

, ATH

Athene Holding

$51.45

0.38 (0.74%)

18:32
02/22/17
02/22
18:32
02/22/17
18:32
Periodicals
Fidelity & Guaranty Life revives sale process, Insurance Insider says »

Fidelity & Guaranty…

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

ATH

Athene Holding

$51.45

0.38 (0.74%)

APO

Apollo Global

$22.25

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:31
02/22/17
02/22
18:31
02/22/17
18:31
Earnings
PRA Health sees Q1 EPS 57c-62c, consensus 67c »

Sees Q1 service revenues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NBR

Nabors Industries

$15.44

0.01 (0.06%)

18:30
02/22/17
02/22
18:30
02/22/17
18:30
Earnings
Nabors Industries reports Q4 EPS ($1.17) with items »

Q4 EPS includes 87c in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:28
02/22/17
02/22
18:28
02/22/17
18:28
Earnings
AxoGen reiterates FY17 revenue growth view of at least 40% »

Management reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:26
02/22/17
02/22
18:26
02/22/17
18:26
Earnings
AxoGen reports Q4 EPS (10c), consensus (9c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

GEN

Genesis Healthcare

$3.83

-0.05 (-1.29%)

18:26
02/22/17
02/22
18:26
02/22/17
18:26
Earnings
Genesis Healthcare sees FY17 revenue $5.4B-$5.6B, consensus $5.64B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

URRE

Uranium Resources

$1.91

-0.06 (-3.05%)

18:25
02/22/17
02/22
18:25
02/22/17
18:25
Hot Stocks
Uranium Resources reports favorable lithium concentrations at Columbus Basin »

Uranium Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEN

Genesis Healthcare

$3.83

-0.05 (-1.29%)

18:24
02/22/17
02/22
18:24
02/22/17
18:24
Earnings
Genesis Healthcare reports Q4 revenue $1.4B, consensus $1.4B »

Reports Q4 net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

MCRI

Monarch Casino

$23.98

-0.22 (-0.91%)

18:22
02/22/17
02/22
18:22
02/22/17
18:22
Earnings
Monarch Casino reports Q4 EPS 36c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMX

CombiMatrix

$4.10

-0.1 (-2.38%)

, UCTT

Ultra Clean

$12.58

0.2 (1.62%)

18:22
02/22/17
02/22
18:22
02/22/17
18:22
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

CBMX

CombiMatrix

$4.10

-0.1 (-2.38%)

UCTT

Ultra Clean

$12.58

0.2 (1.62%)

SQ

Square

$15.04

0.41 (2.80%)

CTRP

Ctrip.com

$47.59

0.53 (1.13%)

TSLA

Tesla

$273.51

-3.88 (-1.40%)

BLCM

Bellicum Pharmaceuticals

$12.79

-0.6 (-4.48%)

LB

Labarge

$58.13

0.43 (0.75%)

TSRA

Tessera

$44.65

-0.2 (-0.45%)

ARRS

ARRIS

$30.70

0.75 (2.50%)

JACK

Jack in the Box

$103.60

-3.77 (-3.51%)

SAM

Boston Beer

$166.85

-1.9 (-1.13%)

ELGX

Endologix

$6.53

0.04 (0.62%)

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

FMI

Foundation Medicine

$23.85

-0.6 (-2.45%)

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

NGD

New Gold

$3.04

-0.08 (-2.56%)

NVDA

NVIDIA

$110.76

-0.31 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 14

    Mar

  • 16

    Mar

  • 16

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 23

    Feb

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.